
STATE OF WISCONSIN,)	
)	
Plaintiff,)	Case No.: 04-CV-1709
)	
v.)	
)	
ABBOTT LABORATORIES, et. al.,)	
)	
Defendants.)	
)	

**ANSWERS AND OBJECTIONS OF SMITHKLINE BEECHAM CORPORATION,
D/B/A GLAXOSMITHKLINE, TO PLAINTIFF’S FIFTH SET OF
INTERROGATORIES TO ALL DEFENDANTS**

Pursuant to Wis. Stat. §§ 804.01 and 804.08, defendant SmithKline Beecham Corporation, d/b/a GlaxoSmithKline (“GSK”), by its attorneys, answers and objects to Plaintiff’s Fifth Set of Interrogatories to All Defendants (“Interrogatory No. 13”) as follows:

PRELIMINARY STATEMENT

1. The answer and objections to Interrogatory No. 13 are made solely for the purposes of this action. GSK’s answer is subject to all objections as to competence, relevance, materiality, propriety, and admissibility, and to any and all other objections that may be applicable at a trial or other hearing or proceeding, all of which objections and grounds are expressly reserved and may be interposed at the time of trial.

2. GSK’s answer and objections shall not be deemed to constitute admissions:
- a. that any particular document or thing exists, is relevant, non-privileged, or admissible in evidence; or
 - b. that any statement or characterization in Interrogatory No. 13 is accurate or complete.

3. GSK’s answer is made based upon the usual interpretation of words contained in Interrogatory No. 13 since no definitions or instructions have been provided.

4. GSK is responding on its own behalf and not on behalf on any other entity.

RESPONSE TO INTERROGATORY NO. 13

INTERROGATORY NO. 13: For each calendar year from 1993 to the present, identify the following:

- (a) the gross annual sales of your drugs in the United States; and
- (b) the percentage of the gross annual sales of your drugs in the United States that is attributable to Medicaid patients, *i.e.*, that results from sales to (or stated differently, reimbursement by) state Medicaid programs.

RESPONSE: GSK objects to Interrogatory No. 13 on the grounds that it is overly broad, unduly burdensome, and the phrases “gross annual sales” and “attributable to Medicaid patients” are vague and ambiguous. GSK also objects to Interrogatory No. 13 on the grounds that it seeks information that is not relevant to the issues in this action and not reasonably calculated to lead to the discovery of admissible evidence, such as: (1) information for GSK products not at issue in this case; (2) information for products purchased outside Wisconsin; (3) information for products not reimbursed by Wisconsin Medicaid; and (4) information for periods after the filing of the initial complaint in this action. GSK further objects to Interrogatory No. 13 to the extent it seeks information that is a matter of public record, is equally available to Plaintiff, or is already in the possession of Plaintiff. GSK also objects to Interrogatory No. 13 to the extent it seeks to expand upon or alter GSK’s obligations under the Wisconsin statutes.

Notwithstanding these objections and without waiving them, GSK answers that it has already produced data from which the answer to part of Interrogatory No. 13 may be obtained.

December 10, 2007

By: _____

Jon P. Axelrod
DEWITT ROSS & STEVENS, S.C.
2 East Mifflin Street, Suite 600
Madison, WI 53703
Tele: (608) 255-8891
Fax: (608) 252-9243

Frederick G. Herold
DECHERT, LLP
2440 W El Camino Real, Suite 700
Mountain View, CA 94040
Tele: (650) 813-4800
Fax: (650) 813-4848

Mark H. Lynch
COVINGTON & BURLING
1201 Pennsylvania Avenue, N.W.
P.O. Box 7566
Washington, D.C. 20044-7566
Tele: (202) 662-6000
Fax: (202) 662-6291

*Counsel for Defendant SmithKline Beecham
Corporation, d/b/a GlaxoSmithKline*

Certificate of Service

I certify that on December 10, 2007 a true and correct copy of the foregoing was served on all counsel of record by Lexis Nexis File & Serve®.